27
27R.F RaySearch Laboratories AB (publ)
- Market cap
- EUR 514M
- P/E
- 28.1x
- P/B
- 7.06x
- ROE
- 22.5%
- Dividend yield
- 2.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 27R.F undervalued?
Graham number27R.F trades 196.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RaySearch Laboratories AB (publ) fundamental analysis
No fundamental analysis for RaySearch Laboratories AB (publ) yet.
RaySearch Laboratories AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning a…
Full company profileRaySearch Laboratories AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RaySearch Laboratories AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 531M | 585M | 627M | 742M | 652M | 642M | 844M | 1.02B | 1.19B | 1.34B | 1.28B |
| Gross Profit | 505M | 548M | 571M | 669M | 608M | 591M | 749M | 916M | 1.09B | 1.24B | 1.14B |
| Operating Income | 188M | 176M | 69.6M | 49.0M | 25.7M | -64.0M | 30.3M | 122M | 251M | 330M | 241M |
| EBITDA | - | 228M | 207M | 252M | 213M | 197M | 341M | 406M | 571M | 587M | 241M |
| Net Income | 151M | 118M | 78.5M | 50.4M | -9.08M | -47.3M | 23.8M | 81.6M | 204M | 228M | 181M |
| EPS | - | 3.43 | 2.29 | 1.47 | -0.26 | -1.38 | 0.69 | 2.38 | 5.94 | 6.64 | 5.45 |
| Balance Sheet | |||||||||||
| Total Assets | 717M | 915M | 1.11B | 1.26B | 1.28B | 1.74B | 1.88B | 1.95B | 2.09B | 1.99B | 1.82B |
| Total Liabilities | 257M | 335M | 448M | 559M | 591M | 1.09B | 1.22B | 1.22B | 1.21B | 1.01B | 1.01B |
| Shareholders' Equity | 460M | 580M | 657M | 705M | 694M | 649M | 657M | 735M | 877M | 985M | 805M |
| Cash & Short-term Investments | 87.7M | 104M | 112M | 114M | 169M | 103M | 160M | 344M | 463M | 407M | 158M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 121M | 147M | 178M | 320M | 332M | 238M | 373M | 492M | 485M | 387M | 336M |
| Capital Expenditure | 107M | 11.0M | 73.3M | 47.2M | 29.7M | 52.0M | 232M | 228M | 218M | 228M | 239M |
| Free Cash Flow | - | -1.34M | -45.2M | 108M | 106M | -17.1M | 125M | 265M | 268M | 159M | 96.9M |
| Ratios | |||||||||||
| ROE | 32.9% | 20.3% | 11.9% | 7.1% | -1.3% | -7.3% | 3.6% | 11.1% | 23.2% | 23.1% | 22.5% |
| ROA | 21.1% | 12.9% | 7.1% | 4.0% | -0.7% | -2.7% | 1.3% | 4.2% | 9.7% | 11.4% | 10.0% |
| Net Profit Margin | 28.5% | 20.1% | 12.5% | 6.8% | -1.4% | -7.4% | 2.8% | 8.0% | 17.1% | 16.9% | 14.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
RaySearch Laboratories AB (publ) dividends
- Dividend yield
- 2.35%
- Forward dividend
- 0.36 EUR
- Payout ratio
- 45.1%
- Ex-dividend date
- May 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SEK 103M | 3.00 | 45.1% |
| 2024 | SEK 68.6M | 2.00 | 33.7% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns RaySearch Laboratories AB (publ)
- Insiders 10.85%
- Institutions 59.45%
- Public & others 29.70%
- Shares outstanding 29.8M
- Free float 27.1M
RaySearch Laboratories AB (publ) company profile
- Company name
- RaySearch Laboratories AB (publ)
- Ticker
- 27R.F
- ISIN
- SE0000135485
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 477
- Fiscal year end
- December
- Address
- EugeniavAegen 18 C, Stockholm, Sweden, 113 68
- Phone
- 46 8 51 05 30 00
- Website
- raysearchlabs.com
About RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; Machine Learning; and Liver Ablation Solutions. The company was founded in 2000 and is headquartered in Stockholm, Sweden.
RaySearch Laboratories AB (publ) management
10- Dr. Johan Lof Ph.D.Founder, CEO, President & Director · born 1969
- Mr. Bjorn HardemarkDeputy Chief Executive Officer · born 1977
- Ms. Nina GrönbergChief Financial Officer · born 1978
- Mr. Kjell ErikssonChief Science Officer · born 1973
- Ms. Carolina Haglund StromlidHead of Investor Relations · born 1972
- Ms. Petra JanssonGeneral Counsel · born 1973
- Ms. Jenna StyanDirector of Corporate Development & Strategy
- Ms. Tove AlteborgGlobal Human Resource Manager · born 1980
- Mr. Fredrik LofmanHead of Machine Learning · born 1978
- Laura AntonovicHead of Strategic Partnerships & RaySearch Laboratories